Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity and metabolic diseases. The company`s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in morbidly obese patients without permanently cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
Website: reshapelifesciences.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (0.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -32 852.8% (LTM)
  • Share price is 3 400.0% higher than minimum and 50.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (0.1x vs 30.0x)

Key Financials (Download financials)

Ticker: RSLS
Share price, USD:  (0.0%)3.92
year average price 3.05  


year start price 2.54 2025-02-13

min close price 0.31 2025-04-17

max close price 6.75 2025-06-03

current price 3.92 2026-02-12
Common stocks: 3 106

Dividend Yield:  0.0%
EV / Sales: -0.1x
Margin (EBITDA LTM / Revenue): -92.9%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 0
Net Debt ($m): -1
EV (Enterprise Value): -1
EBITDA LTM (млн $): -13
Price to Book: 0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-24globenewswire.com

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

2025-07-21globenewswire.com

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

2025-07-01globenewswire.com

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

2025-06-25globenewswire.com

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

2025-06-03globenewswire.com

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

2025-05-21globenewswire.com

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

2025-05-02globenewswire.com

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

2025-04-28globenewswire.com

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

2025-04-07globenewswire.com

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

2025-03-10globenewswire.com

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-05-15 2023-11-09 2023-08-07 2023-05-15 2022-11-14 2022-08-19
acceptedDate 2025-11-14 16:51:53 2025-08-14 17:20:20 2025-04-04 16:10:38 2024-11-14 16:30:34 2024-08-14 16:30:30 2024-05-15 16:50:53 2024-04-01 17:18:35 2023-11-08 18:19:14 2023-08-07 17:26:25 2023-05-15 16:51:10 2023-04-17 16:55:59 2022-11-14 17:23:32 2022-08-19 17:17:44 2022-04-08 17:10:50 2021-03-12 16:12:08
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 34 627 1M 8M 2M 2M 2M 9M 2M 2M 2M 11M 3M 3M 14M 11M
costOfRevenue 16 577 643 000 3M 853 000 831 000 779 000 3M 867 000 1M 1M 4M 697 000 1M 5M 5M
grossProfit 18 050 599 000 5M 1M 1M 1M 6M 1M 1M 1M 7M 2M 2M 8M 6M
grossProfitRatio 0.521 0.482 0.628 0.577 0.599 0.598 0.53 0.535 0.751 0.651
researchAndDevelopmentExpenses 39 677 476 000 2M 399 000 399 000 484 000 2M 542 000 581 000 453 000 3M 588 000 761 000 3M 3M
generalAndAdministrativeExpenses 0 2M 7M 2M 2M 2M 10M 2M 2M 4M 17M 4M 5M 24M 11M
sellingAndMarketingExpenses 0 583 000 3M 719 000 670 000 1M 8M 2M 2M 2M 14M 3M 5M 9M 5M
sellingGeneralAndAdministrativeExpenses 844 344 2M 10M 3M 3M 3M 18M 4M 5M 6M 31M 6M 10M 34M 15M
otherExpenses 8M 68 000 0 0 0 25 000 0 0 6000 2000 0 0 0 0 0
operatingExpenses 9M 3M 12M 3M 3M 3M 20M 4M 5M 7M 34M 7M 11M 36M 19M
costAndExpenses 9M 3M 16M 4M 4M 4M 23M 5M 6M 8M 58M 8M 12M 71M 24M
interestIncome 0 0 14 000 0 4000 0 26 000 5000 9000 0 0 31 000 14 000 0 0
interestExpense 25 604 18 000 0 0 0 -9000 0 0 0 5000 113 000 31 000 14 000 832 000 2M
depreciationAndAmortization 2806 0 22 000 5000 6000 6000 154 000 50 000 49 000 2000 2M 543 000 545 000 2M 2M
ebitda -9M -2M -7M -2M -2M -2M -14M -3M -4M -6M -25M 3M -9M -61M -18M
ebitdaratio -247.405 -1.706 -0.766 -1.042 -1.137 -1.44 -1.981 -2.461 0.998 -3.115
operatingIncome -9M -2M -7M -2M -2M -2M -15M -3M -4M -6M -27M 2M -9M -25M -12M
operatingIncomeRatio -247.14 -1.706 -0.768 -1.045 -1.137 -1.44 -1.764 -2.462 0.804 -3.242
totalOtherIncomeExpensesNet -37 567 -503 000 637 000 186 000 473 999 31 000 4M -428 000 511 000 3M -20M -14M -191 000 -38M -9M
incomeBeforeTax -9M -3M -7M -2M -2M -2M -11M -4M -3M -3M -47M -12M -10M -63M -22M
incomeBeforeTaxRatio -248.225 -2.111 -0.687 -0.804 -1.121 -1.639 -1.548 -1.158 -4.351 -3.308
incomeTaxExpense 0 8000 39 000 6000 15 000 14 000 52 000 3000 4000 14 000 -380 000 -363 000 9000 -274 000 -181 000
netIncome -9M -3M -7M -2M -2M -2M -11M -4M -3M -3M -46M -12M -10M -63M -22M
netIncomeRatio -248.225 -2.118 -0.69 -0.812 -1.128 -1.64 -1.55 -1.164 -4.221 -3.311
eps -29.42 -9 -345.74 -3.11 -3.666 -0.094 -2771.94 -1.02 -1.08 -1.56 -157 897 -26.18 -24.392 -419 004 -503 023
epsdiluted -29.42 -9 -3.11 -3.666 -0.094 -1.02 -1.08 -1.56 -26.18 -24.392
weightedAverageShsOut 292 189 292 189 20 622 508 851 434 870 23M 4107 3M 3M 2M 292.683 451 181 392 594 150.705 43
weightedAverageShsOutDil 292 189 292 189 20 622 508 851 434 870 23M 4107 3M 3M 2M 292.683 451 181 392 594 150.705 43
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-04-04 2024-04-01 2023-04-17 2022-04-08 2021-03-12
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 14 000 26 000 -113 000 -832 000 -2M
ebit -7M -15M -27M -63M -20M
nonOperatingIncomeExcludingInterest 0 -744 000 0 38M 7M
netIncomeFromContinuingOperations -7M -11M -46M -63M -22M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -7M -11M -46M -63M -22M
epsDiluted -345.74 -2771.94 -157 897 -419 004 -503 023

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-05-15 2023-11-09 2023-08-07 2023-05-15 2022-11-14 2022-08-19
acceptedDate 2025-11-14 16:51:53 2025-08-14 17:20:20 2025-04-04 16:10:38 2024-11-14 16:30:34 2024-08-14 16:30:30 2024-05-15 16:50:53 2024-04-01 17:18:35 2023-11-08 18:19:14 2023-08-07 17:26:25 2023-05-15 16:51:10 2023-04-17 16:55:59 2022-11-14 17:23:32 2022-08-19 17:17:44 2022-04-08 17:10:50 2021-03-12 16:12:08
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 6M 4M 693 000 743 000 1M 2M 4M 1M 5M 9M 4M 6M 11M 23M 3M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 6M 4M 693 000 743 000 1M 2M 4M 1M 5M 9M 4M 6M 11M 23M 3M
netReceivables 23 000 775 000 987 000 1M 1M 2M 2M 2M 2M 2M 2M 2M 2M 3M 3M
inventory 0 3M 2M 3M 3M 3M 4M 3M 3M 3M 4M 4M 4M 3M 2M
otherCurrentAssets 307 245 1M 114 000 317 000 406 000 383 000 239 000 94 000 112 000 530 000 184 000 157 000 1M 238 000 209 000
totalCurrentAssets 6M 9M 5M 5M 6M 8M 10M 7M 11M 15M 10M 14M 19M 30M 9M
propertyPlantEquipmentNet 87 034 109 000 154 000 220 000 250 000 280 000 310 000 344 000 956 000 758 000 869 000 1M 1M 2M 1M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 314 191 0 0 0 0 0 0 0 238 000 249 000 260 000 13M 20M 21M 27M
goodwillAndIntangibleAssets 314 191 0 0 0 0 0 0 0 238 000 249 000 260 000 13M 20M 21M 27M
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 -555 000 -3M
taxAssets 0 28 000 22 000 28 000 27 000 27 000 28 000 55 000 57 000 57 000 56 000 0 0 555 000 3M
otherNonCurrentAssets 606 914 29 000 29 000 29 000 29 000 29 000 29 000 29 000 57 000 57 000 46 000 1M 1M 1M 46 000
totalNonCurrentAssets 1M 166 000 205 000 277 000 306 000 336 000 367 000 428 000 1M 1M 1M 15M 22M 24M 28M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 7M 9M 5M 6M 6M 8M 11M 8M 12M 16M 11M 28M 42M 54M 37M
accountPayables 0 1M 2M 2M 1M 1M 2M 1M 2M 2M 2M 2M 3M 3M 4M
shortTermDebt 30 458 104 000 811 000 114 000 226 000 112 000 0 110 000 109 000 86 000 0 255 000 338 000 279 000 4M
taxPayables 0 0 30 000 44 000 58 000 52 000 61 000 54 000 68 000 122 000 119 000 120 000 190 000 307 000 265 000
deferredRevenue 0 0 0 0 318 000 643 000 44 000 657 000 459 000 573 000 510 000 644 000 605 000 549 000 398 000
otherCurrentLiabilities 3M 2M 2M 2M 2M 1M 1M 2M 2M 5M 835 000 5M 6M 321 000 911 000
totalCurrentLiabilities 3M 3M 5M 4M 3M 4M 4M 4M 4M 8M 7M 8M 9M 8M 12M
longTermDebt 8151 0 0 77 000 103 000 127 000 0 175 000 198 000 0 0 0 0 0 9M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 123 000 0 367 000 367 000 615 000
otherNonCurrentLiabilities 0 0 20 000 26 000 54 000 50 999 72 000 100 000 512 000 992 000 0 -3M 5000 300 000 1M
totalNonCurrentLiabilities 8151 0 61 000 103 000 157 000 177 999 223 000 275 000 710 000 992 000 123 000 3M 372 000 667 000 11M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 -3M -3M 0 0 0
capitalLeaseObligations 0 0 156 000 191 000 216 000 127 000 262 000 285 000 307 000 86 000 171 000 255 000 338 000 279 000 477 000
totalLiabilities 3M 3M 5M 4M 3M 4M 4M 5M 5M 9M 7M 8M 10M 8M 23M
preferredStock 0 0 0 0 0 0 0 100 000 512 000 0 0 0 0 0 1000
commonStock 5556 0 20 000 0 29 000 23 000 23 000 3000 3000 3000 1000 23 000 20 000 18 000 6000
retainedEarnings -86M -644M -643M -641M -639M -638M -636M -634M -630M -627M -624M -606M -595M -577M -515M
accumulatedOtherComprehensiveIncomeLoss -68 363 -109 000 -104 000 -88 000 -89 000 -96 000 -88 000 -94 000 -95 000 -93 000 -88 000 -68 000 -72 000 -92 000 -121 000
othertotalStockholdersEquity 89M 650M 643M 642M 642M 637M 637M 635M 627M 627M
totalStockholdersEquity 3M 6M -253 000 1M 3M 5M 7M 3M 7M 8M 4M 21M 32M 44M 14M
totalEquity 4M 6M -253 000 1M 3M 5M 7M 3M 7M 8M 4M 21M 32M 46M 14M
totalLiabilitiesAndStockholdersEquity 7M 9M 6M 6M 8M 8M 12M 16M 28M 42M
minorityInterest 1M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7M 9M 5M 6M 6M 8M 11M 8M 12M 16M 11M 28M 42M 54M 37M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 -555 000 -3M
totalDebt 38 609 104 000 967 000 191 000 216 000 239 000 262 000 285 000 307 000 86 000 171 000 255 000 338 000 279 000 13M
netDebt -6M -4M 274 000 -552 000 -837 000 -2M -4M -1M -4M -9M -4M -6M -11M -22M -2M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-04-04 2024-04-01 2023-04-17 2022-04-08 2021-03-12
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 987 000 2M 2M 3M 3M
otherReceivables 0 0 0 0 0
prepaids 334 000 198 000 81 000 1M 914 000
totalPayables 2M 2M 2M 4M 4M
otherPayables 30 000 61 000 119 000 326 000 265 000
accruedExpenses 0 701 000 4M 2M 2M
capitalLeaseObligationsCurrent 115 000 111 000 171 000 279 000 314 000
capitalLeaseObligationsNonCurrent 41 000 151 000 0 0 163 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 643M 642M 628M 622M 529M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS RSLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-05-15 2023-11-09 2023-08-07 2023-05-15 2022-11-14 2022-08-19
acceptedDate 2025-11-14 16:51:53 2025-08-14 17:20:20 2025-04-04 16:10:38 2024-11-14 16:30:34 2024-08-14 16:30:30 2024-05-15 16:50:53 2024-04-01 17:18:35 2023-11-08 18:19:14 2023-08-07 17:26:25 2023-05-15 16:51:10 2023-04-17 16:55:59 2022-11-14 17:23:32 2022-08-19 17:17:44 2022-04-08 17:10:50 2021-03-12 16:12:08
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -8M -3M -7M -2M -2M -2M -11M -4M -3M -3M -46M -12M -10M -35M -22M
depreciationAndAmortization 1297 4000 22 000 5000 6000 6000 154 000 50 000 49 000 48 000 2M 543 000 545 000 2M 2M
deferredIncomeTax 6000 -2000 6000 -1000 0 1000 28 000 2000 4000 -1000 -423 000 -367 000 -1000 -60 000 -86 000
stockBasedCompensation 547 109 12 000 184 000 32 000 65 000 72 000 766 000 216 000 218 000 222 000 2M 387 000 823 000 12M 1M
changeInWorkingCapital 156 000 -156 000 2M -712 000 258 000 454 000 -4M -218 000 -3M -47 000 709 000 -1M 1M -3M 6000
accountsReceivables 307 293 -649 000 560 000 -191 000 7000 440 000 125 000 -482 000 39 000 21 000 678 000 0 0 -284 000 285 000
inventory 92 000 -20 000 922 000 283 000 64 000 320 000 -465 000 31 000 168 000 108 000 -1M 35 000 -279 000 -369 000 -1M
accountsPayables 1M -939 000 820 000 932 000 0 -259 000 -3M 69 000 -3M 344 000 448 000 0 0 -1M -33 000
otherWorkingCapital -93 000 93 000 -11 000 -2M 187 000 -47 000 -337 000 164 000 -138 000 -520 000 770 000 -1M 79 000 -608 000 956 000
otherNonCashItems 12M -2M 200 000 2M -91 000 -829 000 -2M 704 000 -332 000 -3M 20M 7M 304 000 9M 10M
netCashProvidedByOperatingActivities 4M -4M -4M -311 000 -1M -2M -17M -3M -7M -5M -22M -5M -6M -15M -9M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 -43 000 0 -36 000 -7000 -131 000 -33 000 0 -352 000 -390 000
acquisitionsNet 0 0 0 0 0 0 0 0 33 000 0 39 000 0 0 2M -2M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 -39 000 0 0 0 0
salesMaturitiesOfInvestments -16M 11M 0 0 0 0 0 0 0 10M 639 000 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 -10M 0 18 000
netCashUsedForInvestingActivites -16M 11M 0 0 0 0 -3000 -7000 -33 000 18 000
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 679 633 0 -24 000 24 000 0 -338 000 2M 10M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -2M 6M 0 24 000 0 -13M 2M 0 3000 2M
netCashUsedProvidedByFinancingActivities -2M 6M 0 24 000 0 -338 000 2M 10M 3000 2M
effectOfForexChangesOnCash -10 193 1000 -16 000 1000 7000 -8000 0 0 -1000 -5000 4000 4000 -1000 29 000 -113 000
netChangeInCash 1M 2M -4M -310 000 -1M -2M 604 000 -3M -4M 5M -19M -5M -4M 20M 22 000
cashAtEndOfPeriod 6M 4M 793 000 843 000 1M 2M 5M 2M 5M 9M 4M 6M 12M 23M 3M
cashAtBeginningOfPeriod 4M 3M 5M 1M 2M 5M 4M 5M 9M 4M 23M 12M 15M 3M 3M
operatingCashFlow 4M -4M -4M -311 000 -1M -2M -17M -3M -7M -5M -22M -5M -6M -15M -9M
capitalExpenditure 0 0 0 0 0 0 -43 000 0 -36 000 -7000 -131 000 -33 000 -12 000 -352 000 -390 000
freeCashFlow 4M -4M -4M -311 000 -1M -2M -17M -3M -7M -5M -22M -5M -6M -16M -9M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-04-04 2024-04-01 2023-04-17 2022-04-08 2021-03-12
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 33 000 -600 000 0 0
netCashProvidedByInvestingActivities 0 -10000 -92 000 2M -2M
netDebtIssuance 653 000 0 0 -10M 10M
longTermNetDebtIssuance 653 000 0 0 -10M 10M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 24 000 18M 639 000 43M 679 000
netCommonStockIssuance 24 000 18M 639 000 43M 679 000
commonStockIssuance 24 000 18M 639 000 43M 679 000
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 2M 0 -59 000
netCashProvidedByFinancingActivities 677 000 18M 3M 33M 11M
incomeTaxesPaid 12 000 10000 5000 102 000 40 000
interestPaid 0 0 0 296 000 0

Earning call transcript

2024 q3
2024-11-14 ET (fiscal 2024 q3)
2024 q2
2024-08-15 ET (fiscal 2024 q2)
2024 q1
2024-05-17 ET (fiscal 2024 q1)
2023 q4
2024-04-01 ET (fiscal 2023 q4)
2023 q3
2023-11-10 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-15 ET (fiscal 2023 q1)
2022 q4
2023-04-29 ET (fiscal 2022 q4)
2022 q3
2022-11-14 ET (fiscal 2022 q3)
2022 q2
2022-08-15 ET (fiscal 2022 q2)
2022 q1
2022-05-23 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-12-23 16:10 ET
ReShape Lifesciences published news for 2025 q3
SEC form 8
2025-12-23 16:10 ET
ReShape Lifesciences published news for 2025 q3
SEC form 8
2025-11-19 17:21 ET
ReShape Lifesciences published news for 2025 q3
SEC form 8
2025-11-19 17:21 ET
ReShape Lifesciences reported for 2025 q3
SEC form 10
2025-11-14 21:51 ET
ReShape Lifesciences published news for 2025 q3
SEC form 8
2025-10-03 20:44 ET
ReShape Lifesciences published news for 2025 q3
SEC form 8
2025-10-03 20:44 ET
ReShape Lifesciences published news for 2025 q3
SEC form 8
2025-09-02 12:04 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-09-02 12:04 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-09-02 12:04 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-09-02 12:04 ET
ReShape Lifesciences published news for 2025 q2
SEC form 10
2025-08-14 21:20 ET
ReShape Lifesciences reported for 2025 q2
SEC form 8
2025-07-15 20:06 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-07-15 20:06 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-07-03 20:05 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-07-03 20:05 ET
ReShape Lifesciences published news for 2025 q2
SEC form 8
2025-06-12 20:18 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-06-12 20:18 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-06-12 20:18 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-06-12 20:18 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-06-12 20:18 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-30 20:07 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-30 20:07 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-30 20:07 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-28 11:00 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-28 11:00 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-28 11:00 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-28 11:00 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-28 11:00 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-05-28 11:00 ET
ReShape Lifesciences published news for 2025 q1
SEC form 10
2025-05-20 20:56 ET
ReShape Lifesciences reported for 2025 q1
SEC form 8
2025-04-28 20:05 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-04-28 20:05 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-04-21 20:11 ET
ReShape Lifesciences published news for 2025 q1
SEC form 8
2025-04-21 20:11 ET
ReShape Lifesciences published news for 2025 q1
SEC form 10
2025-04-04 16:10 ET
ReShape Lifesciences reported for 2024 q4
SEC form 10
2025-04-04 00:00 ET
ReShape Lifesciences reported for 2024 q4
SEC form 8
2025-02-20 21:05 ET
ReShape Lifesciences published news for 2024 q4
SEC form 8
2025-02-20 21:05 ET
ReShape Lifesciences published news for 2024 q4
SEC form 8
2025-02-20 21:05 ET
ReShape Lifesciences published news for 2024 q4
SEC form 8
2025-02-20 21:05 ET
ReShape Lifesciences published news for 2024 q4
SEC form 10
2024-11-14 16:30 ET
ReShape Lifesciences reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
ReShape Lifesciences reported for 2024 q3
SEC form 8
2024-11-14 00:00 ET
ReShape Lifesciences published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
ReShape Lifesciences reported for 2024 q3
SEC form 10
2024-08-14 00:00 ET
ReShape Lifesciences reported for 2024 q2
SEC form 8
2024-08-14 00:00 ET
ReShape Lifesciences published news for 2024 q2
SEC form 8
2024-08-14 00:00 ET
ReShape Lifesciences reported for 2024 q2
SEC form 8
2024-05-20 00:00 ET
ReShape Lifesciences published news for 2024 q1
SEC form 8
2024-05-20 00:00 ET
ReShape Lifesciences reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
ReShape Lifesciences reported for 2024 q1
SEC form 8
2024-04-04 00:00 ET
ReShape Lifesciences published news for 2024 q1
SEC form 8
2024-04-04 00:00 ET
ReShape Lifesciences published news for 2024 q1
SEC form 10
2024-04-01 00:00 ET
ReShape Lifesciences reported for 2023 q4
SEC form 10
2023-11-09 00:00 ET
ReShape Lifesciences reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
ReShape Lifesciences reported for 2023 q3
SEC form 10
2023-08-07 00:00 ET
ReShape Lifesciences reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
ReShape Lifesciences reported for 2023 q2
SEC form 8
2023-05-16 00:00 ET
ReShape Lifesciences reported for 2023 q1
SEC form 6
2023-05-15 17:40 ET
ReShape Lifesciences reported for 2023 q1
SEC form 10
2023-05-15 16:51 ET
ReShape Lifesciences reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
ReShape Lifesciences reported for 2023 q1
SEC form 6
2023-04-26 16:06 ET
ReShape Lifesciences published news for 2023 q1
SEC form 10
2023-04-17 16:55 ET
ReShape Lifesciences reported for 2022 q4
SEC form 10
2023-04-17 00:00 ET
ReShape Lifesciences reported for 2022 q4
SEC form 6
2023-04-13 17:24 ET
ReShape Lifesciences published news for 2023 q1
SEC form 6
2023-04-03 17:11 ET
ReShape Lifesciences published news for 2023 q1
SEC form 6
2023-03-21 16:18 ET
ReShape Lifesciences published news for 2022 q4
SEC form 6
2023-02-10 16:05 ET
ReShape Lifesciences published news for 2022 q4
SEC form 6
2023-01-27 06:06 ET
ReShape Lifesciences published news for 2022 q4
SEC form 6
2022-12-28 16:18 ET
ReShape Lifesciences published news for 2022 q3
SEC form 6
2022-12-20 17:30 ET
ReShape Lifesciences published news for 2022 q3
SEC form 10
2022-11-14 17:23 ET
ReShape Lifesciences reported for 2022 q3
SEC form 6
2022-11-14 16:54 ET
ReShape Lifesciences published news for 2022 q3
SEC form 6
2022-11-14 06:19 ET
ReShape Lifesciences published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
ReShape Lifesciences reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
ReShape Lifesciences reported for 2022 q3
SEC form 6
2022-11-10 16:55 ET
ReShape Lifesciences published news for 2022 q3
SEC form 6
2022-10-31 16:02 ET
ReShape Lifesciences published news for 2022 q3
SEC form 10
2022-08-19 17:17 ET
ReShape Lifesciences reported for 2022 q2
SEC form 10
2022-08-19 00:00 ET
ReShape Lifesciences reported for 2022 q2
SEC form 8
2022-08-16 00:00 ET
ReShape Lifesciences reported for 2022 q2
SEC form 6
2022-08-15 20:07 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-08-15 18:31 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-08-02 16:09 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-07-25 16:05 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-07-21 16:05 ET
ReShape Lifesciences published news for 2022 q2
SEC form 6
2022-06-23 16:38 ET
ReShape Lifesciences published news for 2022 q1
SEC form 10
2022-05-23 15:13 ET
ReShape Lifesciences reported for 2022 q1
SEC form 6
2022-05-23 10:33 ET
ReShape Lifesciences published news for 2022 q1
SEC form 10
2022-05-23 00:00 ET
ReShape Lifesciences reported for 2022 q1
SEC form 8
2022-05-23 00:00 ET
ReShape Lifesciences reported for 2022 q1
SEC form 6
2022-05-13 17:15 ET
ReShape Lifesciences published news for 2022 q1
SEC form 6
2022-04-14 17:12 ET
ReShape Lifesciences published news for 2022 q1
SEC form 10
2022-04-08 17:10 ET
ReShape Lifesciences published news for 2021 q4
SEC form 10
2022-04-08 00:00 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-31 20:23 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-28 17:30 ET
ReShape Lifesciences published news for 2021 q4
SEC form 8
2022-03-28 00:00 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-21 19:01 ET
ReShape Lifesciences published news for 2021 q4
SEC form 6
2022-03-17 08:35 ET
ReShape Lifesciences published news for 2021 q4
SEC form 8
2022-03-17 00:00 ET
ReShape Lifesciences published news for 2021 q4
SEC form 10
2021-11-12 15:43 ET
ReShape Lifesciences published news for 2021 q3
SEC form 6
2021-11-12 15:38 ET
ReShape Lifesciences published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
ReShape Lifesciences published news for 2021 q3
SEC form 8
2021-11-12 00:00 ET
ReShape Lifesciences published news for 2021 q3
SEC form 10
2021-08-16 11:36 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-08-16 11:18 ET
ReShape Lifesciences published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
ReShape Lifesciences published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-07-19 08:01 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-07-02 16:05 ET
ReShape Lifesciences published news for 2021 q2
SEC form 6
2021-06-15 17:11 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-06-15 12:20 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-26 06:02 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-21 09:02 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-18 16:07 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-13 16:03 ET
ReShape Lifesciences published news for 2021 q1
SEC form 10
2021-05-12 08:32 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-12 08:30 ET
ReShape Lifesciences published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
ReShape Lifesciences published news for 2021 q1
SEC form 6
2021-05-04 16:03 ET
ReShape Lifesciences published news for 2021 q1
SEC form 10
2021-03-12 16:12 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-03-12 16:10 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-02-10 16:05 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-01-22 16:15 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2021-01-20 08:33 ET
ReShape Lifesciences published news for 2020 q4
SEC form 6
2020-12-18 06:06 ET
ReShape Lifesciences published news for 2020 q3
SEC form 6
2020-12-15 16:15 ET
ReShape Lifesciences published news for 2020 q3
SEC form 6
2020-11-06 16:46 ET
ReShape Lifesciences published news for 2020 q3
SEC form 10
2020-11-06 16:31 ET
ReShape Lifesciences published news for 2020 q3